Sarepta establishes new manufacturing facility in Massachusetts

Sarepta Therapeutics, Inc. has reached an agreement to acquire a 60,000-square-foot manufacturing facility in Massachusetts, according to Boston Business Journal. The location will be used to increase the scale of its manufacturing of phosphorodiamidate morpholino oligomer chemistries for RNA therapeutics as well as develop investigational exon skipping therapies for Duchenne muscular dystrophy.

The company will invest approximately $25 million to acquire and renovate the building, which was qualified under the U.S. Food and Drug Administration's Current Good Manufacturing Practice regulations. The parties expect to close the deal in July subject to the conditions and extensions in their agreement. When the facilities renovations are finished and it's fully operational, it'll need 40 technicians and support staff to operate, some of which will be new hires. 

Sarepta is moving forward with its plan to expand operations in the U.S. because it expects their lead product, Eteplirsen, will be approved by the FDA for sale next year, according to the company statement.

Companies looking to expand their pharmaceutical production should work with technology recruiters who can connect them with the most qualified candidates for their open positions.